43101-34-4Relevant academic research and scientific papers
COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
-
Page/Page column 366, (2017/09/15)
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
Observations on the reductive ring opening reactions of alkylidenecyclopropyl ketones promoted by lithium in liquid ammonia
Motherwell, William B.,Zuberi, Sheena
, p. 8789 - 8791 (2007/10/03)
The regio- and stereochemical outcome of the reductive ring opening reactions of alkylidenecyclopropyl ketones is a function of substrate structure.
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
-
Page 43-44, (2008/06/13)
Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals The invention relates to cycloalkyl derivatives having bioisosteric carboxylic acid groups and to their physiologically acceptable salts and physiologically functional derivatives. What is described are compounds of the formula 1, in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistence is involved.
